Efficacy of black garlic extract on anti-tumor and anti-oxidant activity enhancement in rats

Abstract

ObjectiveThe current study aimed to investigate the effect of oral administration of aqueous aged garlic extract (AGE) on the anti-tumor activity of diethylnitrosoamine (DEN)-induced hepatocarcinogenic rats for 7 weeks.MethodsForty-five male Wistar rats were randomly divided into five groups (n = 9) as follows: Groups A (control); B (DEN-group) received a single intraperitoneal (i.p.) injection of DEN and a dose of and Carbon tetrachloride (CCl4) two weeks later; C, D, and E received the same carcinogenesis protocol as B plus AGE oral doses 150, 300, and 600 mg/Kg/d, respectively, for 7 weeks. Liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL), and serum and liver glutathione reductase (GR) activity, and serum Trolox Equivalent Antioxidant Capacity (TEAC) were measured.ResultsThe present study revealed that administration of AGE doses 300 mg/Kg/d (group D) and 600 mg/Kg/d group (E), for 7 weeks, significantly (p < 0.01) decreased liver weight, relative to that in group B, with significantly decreased (p < 0.01) serum ALT, AST, and TBIL levels. It also showed that AGE improved liver and serum GR activity levels and serum TEAC levels than in group B.ConclusionThis finding suggests that AGE has remarkable hepatoprotective and antioxidant effects in DEN-induced hepatocarcinogenic rats. Further studies are needed to demonstrate effective various doses of AGE in human. The mechanisms underlying the active principle responsible for the anti-tumor activity and need to be elucidated in future studies. The current study aimed to investigate the effect of oral administration of aqueous aged garlic extract (AGE) on the anti-tumor activity of diethylnitrosoamine (DEN)-induced hepatocarcinogenic rats for 7 weeks. Forty-five male Wistar rats were randomly divided into five groups (n = 9) as follows: Groups A (control); B (DEN-group) received a single intraperitoneal (i.p.) injection of DEN and a dose of and Carbon tetrachloride (CCl4) two weeks later; C, D, and E received the same carcinogenesis protocol as B plus AGE oral doses 150, 300, and 600 mg/Kg/d, respectively, for 7 weeks. Liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL), and serum and liver glutathione reductase (GR) activity, and serum Trolox Equivalent Antioxidant Capacity (TEAC) were measured. The present study revealed that administration of AGE doses 300 mg/Kg/d (group D) and 600 mg/Kg/d group (E), for 7 weeks, significantly (p < 0.01) decreased liver weight, relative to that in group B, with significantly decreased (p < 0.01) serum ALT, AST, and TBIL levels. It also showed that AGE improved liver and serum GR activity levels and serum TEAC levels than in group B. This finding suggests that AGE has remarkable hepatoprotective and antioxidant effects in DEN-induced hepatocarcinogenic rats. Further studies are needed to demonstrate effective various doses of AGE in human. The mechanisms underlying the active principle responsible for the anti-tumor activity and need to be elucidated in future studies.